Oral Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Formulation (Tablets, Capsules, Drops, Liquid or Syrup), By Type (Controlled Release, Orodispersible Tablets, Others), By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others), By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Oral Drug Delivery Market, valued at USD 129.77 Billion in 2024, is projected to experience a CAGR of 7.80% to reach USD 203.65 Billion by 2030. The Global Oral Drug Delivery Market encompasses the segment of the pharmaceutical industry dedicated to developing, manufacturing, and commercializing therapeutic agents administered via the oral route. This method is highly favored due to its inherent patient convenience, ease of administration, and potential for improved compliance compared to other delivery methods. Key drivers propelling this market include the increasing global prevalence of chronic diseases such as cardiovascular conditions, diabetes, and cancer, which necessitate long-term medication regimens. Additionally, the rising geriatric population worldwide and the growing demand for self-administration and home care facilities significantly contribute to market expansion.

Despite robust growth drivers, a significant challenge impeding market expansion is the stringent regulatory approval processes. This complexity can lead to delays and increased costs in bringing new oral formulations to market. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2024, only 46% of innovative medicines approved centrally in the period 2020-2023 were available to European patients, highlighting access hurdles within the broader pharmaceutical sector.

Key Market Drivers

Technological advancements in drug delivery systems and expanded investment in pharmaceutical research and development exert considerable influence on the Global Oral Drug Delivery Market. Innovations in solubility enhancement, controlled release mechanisms, and targeted delivery are broadening the range of orally administered therapies, including complex molecules once limited to injectable routes. These developments improve drug stability, bioavailability, and therapeutic precision. For instance, according to Fierce Biotech, in April 2025, Roche acquired Carmot Therapeutics for $2.7 billion in late 2023, securing access to three GLP-1 receptor agonists with potential for treating obesity, including oral administration. Such strategic investments emphasize the industry's dedication to patient-friendly oral formulations.

The rising global prevalence of chronic diseases is another potent driver for the oral drug delivery market. Conditions such as diabetes, cardiovascular diseases, and various cancers require long-term medication, making convenient oral therapies highly desirable for improved patient adherence and quality of life. This demographic shift generates sustained demand for effective, easily administrable drugs. According to the International Diabetes Federation (IDF) Diabetes Atlas, in April 2025, approximately 589 million adults aged 20-79 were living with diabetes globally in 2024. This significant patient population fuels the imperative for novel oral drug formulations. Moreover, according to BioWorld, in January 2024, large pharma corporations' R&D expenditure totaled a record $161 billion in 2023, showcasing a robust commitment to addressing widespread health challenges through diverse drug delivery platforms.

Download Free Sample Report

Key Market Challenges

A significant challenge impeding market expansion for oral drug delivery is the stringent regulatory approval processes. These complex procedures inherently increase the time and financial investment required to bring new oral formulations to market. This extended development timeline and heightened cost create substantial barriers for pharmaceutical companies, particularly those developing innovative therapies, by prolonging the period before potential revenue generation.

This regulatory burden directly hampers market growth by delaying patient access to new oral medications. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in its 2024 Patients W. A. I. T. Indicator Survey, the average time to reimbursement for innovative treatments across EU and European Economic Area countries reached 578 days. Such delays defer commercialization opportunities and impact the return on investment for drug developers. The protracted approval pathways can also deter new entrants and reduce overall innovation within the oral drug delivery segment due to the increased risk and expense associated with navigating these rigorous frameworks.

Key Market Trends

The development of personalized oral therapies is a significant trend reshaping the Global Oral Drug Delivery Market by moving towards treatments tailored to individual patient profiles. This approach leverages advancements in diagnostics and genomics to customize drug selection, dosage, and formulation, enhancing therapeutic efficacy and minimizing adverse effects. According to the Personalized Medicine Coalition (PMC), in 2024, the FDA approved 18 new personalized medicines, representing approximately 38 percent of all newly approved therapeutic molecular entities. These approvals underscore a growing industry commitment to individualized treatment pathways. For instance, Eli Lilly and Company announced positive topline results in April 2025 from a Phase 3 clinical trial for orforglipron, an investigational once-daily oral medication for type 2 diabetes, which could provide a new, tailored option for patients seeking non-injectable therapy. This shift ultimately improves patient outcomes and adherence, particularly for chronic conditions requiring long-term medication.

The adoption of smart pill technology is another pivotal trend, integrating digital capabilities directly into oral drug delivery systems. Smart pills, or ingestible sensors, are designed to monitor physiological parameters, track medication adherence, and facilitate targeted drug release in real-time. This technology enables enhanced diagnostic precision and dynamic therapeutic adjustments, moving beyond traditional passive drug delivery. The European Federation of Pharmaceutical Industries and Associations (EFPIA) highlighted that by January 2023, Germany had 40 authorized and reimbursed digital therapeutics, signifying a growing regulatory acceptance and market infrastructure for advanced digital health solutions, including ingestible technologies. Further demonstrating this trend, the International Journal of Engineering Research & Technology reported in July 2025 that the global market for digital pills and ingestible sensors was projected to reach USD 3.29 billion by 2033, driven by the need for remote monitoring and technological advancements. This integration offers significant potential for improving patient engagement and treatment effectiveness in managing various diseases.

Segmental Insights

In the Global Oral Drug Delivery Market, tablets are emerging as the fastest-growing segment, primarily driven by their inherent advantages and continuous technological advancements. Tablets offer superior patient convenience due to their ease of self-administration, accurate dosing capabilities, and long shelf-life stemming from robust physical and chemical stability. Furthermore, their cost-effective manufacturing processes make them an economically viable option for pharmaceutical companies. Ongoing innovation in formulation, including controlled-release mechanisms and orally disintegrating forms, enhances therapeutic efficacy and patient compliance. Supportive regulatory frameworks, with clear guidance from bodies such as the Food and Drug Administration (FDA) for solid oral dosage forms, further facilitate their development and market entry.

Regional Insights

North America leads the global oral drug delivery market, driven by its robust research and development infrastructure and significant healthcare expenditure. The region benefits from the strong presence of major pharmaceutical companies that continuously invest in novel drug formulations and advanced delivery technologies. A well-established regulatory framework, notably the U. S. Food and Drug Administration (FDA) and Health Canada, provides a supportive environment for the development and expedited approval of innovative oral delivery systems, ensuring product safety and efficacy. Furthermore, the high prevalence of chronic diseases across the region fuels a consistent demand for effective and patient-friendly oral medication options, aligning with patient preference for convenient administration over invasive methods.

Recent Developments

• In August 2025, BioMed X and Novo Nordisk initiated a new collaboration focused on the efficient oral delivery of therapeutic peptides. This partnership aims to address key challenges in formulating peptide drugs, such as low intestinal permeability and rapid gastrointestinal transit. The joint research project, titled 'Prolonged Retention of Oral Peptide Formulations in the Gut,' seeks to develop novel oral formulation technologies to achieve site-specific, prolonged retention of dosage forms within the lower small intestine. The objective is to significantly enhance the absorption and bioavailability of peptide-based therapeutics, impacting the global oral drug delivery landscape.

• In June 2025, Sanofi completed the acquisition of Blueprint Medicines, expanding its immunology portfolio. The acquisition included BLU-808, a highly selective and potent oral wild-type KIT inhibitor. This oral drug candidate holds potential for treating a broad spectrum of immunological diseases, thereby strengthening Sanofi's presence in the global oral drug delivery market for specialized therapies. The transaction, valued at approximately $9.1 billion in equity, also involved potential future milestone payments to Blueprint shareholders for the development and regulatory achievements of BLU-808.

• In October 2024, Taho Pharmaceuticals Ltd. and Mithradote Bio Inc. announced a collaboration to develop an oral delivery formulation for Mithradote Bio's M-101. This partnership focuses on advancing M-101 through an optimized oral delivery system, which is crucial for improving patient access and convenience in the global oral drug delivery market. The agreement leverages Taho Pharmaceuticals' expertise in formulation development to ensure the effective oral administration of Mithradote Bio's therapeutic candidate. The specific financial terms of this collaboration were not disclosed.

• In February 2024, CD Formulation introduced its Oral Thin Film Technology, marking a significant advancement in the global oral drug delivery market. This novel system facilitates medication administration by utilizing thin film strips that dissolve rapidly in the oral cavity, directly releasing medication into the bloodstream. This method bypasses the digestive system, aiming for quicker absorption and enhanced bioavailability. The technology offers advantages for patients with swallowing difficulties, such as children and the elderly, improving adherence and convenience. The company highlighted that this innovation is poised to refine medication delivery by offering precise dosing and a more patient-centric approach to treatment.

Key Market Players

• Novartis AG
• Biocon Ltd.
• NovoNordisk A/S
• F.Hoffmann-La Roche Ltd.
• Bayer AG
• Emishphere Technologies Inc.
• Enteris Biopharma Inc.
• Merrion Pharmaceuticals Plc.
• Amgen Inc.
• Pfizer Inc.

Report Scope:

In this report, the Global Oral Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Oral Drug Delivery Market, By Formulation:

o   Tablets

o   Capsules

o   Drops

o   Liquid or Syrup

• Oral Drug Delivery Market, By Type:

o   Controlled Release

o   Orodispersible Tablets

o   Others

• Oral Drug Delivery Market, By Therapy Area:

o   Oncology

o   Musculoskeletal

o   Immunology

o   Gastrointestinal

o   Respiratory

o   Cardiovascular

o   Others

• Oral Drug Delivery Market, By End User:

o   Hospitals

o   Ambulatory Surgical Centres

o   Diagnostic Centres

o   Clinics

o   Others

• Oral Drug Delivery Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Oral Drug Delivery Market.

Available Customizations:

Global Oral Drug Delivery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Oral Drug Delivery Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]